Semaglutide
KaiNETIC-3
Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 1270
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Ribupatide: Dose 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Ribupatide: Dose 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Semaglutide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |